Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea’s Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)
SUMMARY
GBI Research, the leading business intelligence provider, has released its latest research, "Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea’s Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)", which provides insights into the global ophthalmology therapeutics market, with forecasts until 2018. The report provides an in-depth analysis of the key therapeutic indications of ophthalmology, namely glaucoma, allergic conjunctivitis, Dry Eye Syndrome (DES), Diabetic Macular Edema (DME), and Wet Age Macular Degeneration (Wet-AMD). The report also examines the ophthalmology therapeutics treatment usage patterns for the covered indications. In addition, the report includes insights into the ophthalmology R&D pipeline.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
In 2011, the global ophthalmology therapeutics market was estimated to be around $10 billion, growing at a Compound Annual Growth Rate (CAGR) of 7.2% between 2004 and 2011. The glaucoma market was the largest segment followed by Wet-AMD. These segments accounted for 36% and 32% of the global ophthalmology therapeutics market in 2011, respectively. The decline in glaucoma revenue due to significant generic erosion will change the therapeutic landscape until 2018, when glaucoma is expected to account for 23%, a decline of 13% relative to 2011, and the wet-AMD market is expected to account for 37% of the global ophthalmology market, an increase of 5% relative to 2011. The decline in the glaucoma market is expected to be offset by a healthy growth in the wet-AMD, DME, and DES markets. These markets are expected to grow due to the presence of considerable unmet need and increasing treatment-seeking and diagnosis rates.
The top pharmaceutical companies in the ophthalmology market are Pfizer Inc., Allergan Inc., Alcon Inc, Novartis AG., Merck & co. Inc and Roche. Approximately 70% of the market is covered by these six companies.
SCOPE
SUMMARY
GBI Research, the leading business intelligence provider, has released its latest research, "Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea’s Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)", which provides insights into the global ophthalmology therapeutics market, with forecasts until 2018. The report provides an in-depth analysis of the key therapeutic indications of ophthalmology, namely glaucoma, allergic conjunctivitis, Dry Eye Syndrome (DES), Diabetic Macular Edema (DME), and Wet Age Macular Degeneration (Wet-AMD). The report also examines the ophthalmology therapeutics treatment usage patterns for the covered indications. In addition, the report includes insights into the ophthalmology R&D pipeline.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
In 2011, the global ophthalmology therapeutics market was estimated to be around $10 billion, growing at a Compound Annual Growth Rate (CAGR) of 7.2% between 2004 and 2011. The glaucoma market was the largest segment followed by Wet-AMD. These segments accounted for 36% and 32% of the global ophthalmology therapeutics market in 2011, respectively. The decline in glaucoma revenue due to significant generic erosion will change the therapeutic landscape until 2018, when glaucoma is expected to account for 23%, a decline of 13% relative to 2011, and the wet-AMD market is expected to account for 37% of the global ophthalmology market, an increase of 5% relative to 2011. The decline in the glaucoma market is expected to be offset by a healthy growth in the wet-AMD, DME, and DES markets. These markets are expected to grow due to the presence of considerable unmet need and increasing treatment-seeking and diagnosis rates.
The top pharmaceutical companies in the ophthalmology market are Pfizer Inc., Allergan Inc., Alcon Inc, Novartis AG., Merck & co. Inc and Roche. Approximately 70% of the market is covered by these six companies.
SCOPE
- The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the glaucoma, allergic conjunctivitis, DES, DME, and wet-AMD therapeutics market.
- Data and analysis for the global ophthalmology therapeutics market
- Annualized market data for the ophthalmology therapeutics market from 2004 to 2011, with forecasts to 2018
- Key drivers and restraints that have had a significant impact on the market
- The competitive landscape of the global ophthalmology therapeutics market
- Key M&A activities and licensing agreements that took place in the ophthalmology therapeutics market
- Align your product portfolio to the markets with high growth potential
- Develop market entry and market expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the ophthalmology market
- Develop key strategic initiatives by understanding the key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
1 TABLE OF CONTENTS
1.1 List Of Tables
1.2 List Of Figures
2 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - INTRODUCTION
2.1 Overview
3 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - MARKET OVERVIEW
3.1 IntrodUction
3.2 RevenUe
3.3 AnnUal Cost of Treatment
3.4 Treatment Usage Pattern
3.5 Branded and Generic Market Share
4 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - GEOGRAPHICAL LANDSCAPE
4.1 Geographical Break-Up
4.1.1 The US
4.1.2 Top Five CoUntries in EUrope
4.1.3 Japan
5 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - THERAPEUTIC LANDSCAPE
5.1 GlaUcoma Therapeutics Market
5.1.1 IntrodUction
5.1.2 RevenUe
5.1.3 AnnUal Cost of Treatment
5.1.4 Treatment Usage Pattern
5.1.5 Treatment Flow Algorithm
5.1.6 Branded and Generic Market Share
5.1.7 Drivers for the GlaUcoma Therapeutics Market
5.1.8 Restraints for GlaUcoma Therapeutics Market
5.1.9 Geographical Segmentation
5.2 Allergic ConjUnctivitis Therapeutics Market
5.2.1 IntrodUction
5.2.2 RevenUe
5.2.3 AnnUal Cost of Treatment
5.2.4 Treatment Usage Pattern
5.2.5 Treatment Flow Algorithm
5.2.6 Branded and Generic Market Share
5.2.7 Geographical Segmentation
5.3 Wet Age MacUlar Degeneration Therapeutics Market
5.3.1 IntrodUction
5.3.2 RevenUe
5.3.3 AnnUal Cost of Treatment
5.3.4 Treatment Usage Pattern
5.3.5 Treatment Flow Algorithm
5.3.6 Branded and Generic Market Share
5.3.7 Drivers for Wet Age-related MacUlar Degeneration Therapeutics Market
5.3.8 Restraints for Wet Age-Related MacUlar Degeneration Therapeutics Market
5.3.9 Geographical Segmentation
5.4 Diabetic MacUlar Edema Therapeutics Market
5.4.1 IntrodUction
5.4.2 RevenUe
5.4.3 AnnUal Cost of Treatment
5.4.4 Treatment Usage Pattern
5.4.5 Treatment Flow Algorithm
5.4.6 Drivers for Diabetic MacUlar Edema Therapeutics Market
5.4.7 Restraints for Diabetic MacUlar Edema Therapeutics Market
5.4.8 Geographical Segmentation
5.5 Dry Eye Syndrome, Therapeutics Market
5.5.1 IntrodUction
5.5.2 RevenUe
5.5.3 AnnUal Cost of Treatment
5.5.4 Treatment Usage Pattern
5.5.5 Treatment Flow Algorithm
5.5.6 Branded and Generic Market Share
5.5.7 Drivers for Dry Eye Syndrome Therapeutics Market
5.5.8 Restraints for Dry Eye Syndrome Therapeutics Market
5.5.9 Geographical Segmentation
6 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - APAC
6.1 India
6.1.1 Overview
6.1.2 Key Trends
6.1.3 Key Strategies
6.2 China
6.2.1 Overview
6.2.2 Key Trends
6.2.3 Key Strategies
6.3 AUstralia
6.3.1 Overview
6.3.2 Pricing and ReimbUrsement
7 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - PROFILES OF PROMISING PIPELINE PRODUCTS
7.1 IlUvien (flUocinolone acetonide)
7.1.1 Overview
7.1.2 Efficacy
7.1.3 Safety
7.1.4 Clinical StUdy Details
7.2 Rebamipide (OPC-12759E)
7.2.1 Overview
7.2.2 Clinical Details
7.3 RemUra (bromfenac)
7.3.1 Overview
7.3.2 Clinical details
7.4 OzUrdex (dexamethasone)
7.4.1 Overview
7.4.2 Clinical Details
7.5 ISTA -Ecabet SodiUm
7.5.1 Overview
7.6 Allergan’s Androgen Tear
7.6.1 Overview
8 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - COMPETITIVE LANDSCAPE
8.1 Allergan, Inc.
8.1.1 BUsiness Overview
8.1.2 SWOT
8.2 Merck & Co Inc
8.2.1 IntrodUction
8.2.2 SWOT
8.3 Novartis AG
8.3.1 IntrodUction
8.3.2 SWOT
8.4 Pfizer
8.4.1 BUsiness Description
8.4.2 SWOT
8.5 Roche
8.5.1 IntrodUction
8.5.2 SWOT
9 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - STRATEGIC CONSOLIDATIONS
9.1 Mergers and AcqUisitions
9.1.1 IntrodUction
9.1.2 Key Mergers and AcqUisitions Deals
9.1.3 Segmentation by Geography
9.1.4 Segmentation by Deal ValUe
9.2 Co-development Deals
9.2.1 Major Co-development Deals
9.2.2 Segmentation by Geography
9.3 Licensing Deals
9.3.1 Major Licensing Deals
9.3.2 Segmentation by Geography
9.3.3 Segmentation by ValUe
10 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Primary Research
10.5 Therapeutic Landscape
10.5.2 Market Size by Geography
10.6 Geographical Landscape
10.7 Pipeline Analysis
10.8 Competitive Landscape
10.8.1 Expert Panel Validation
10.9 Contact Us
10.10 Disclaimer
LIST OF TABLES
Table 1: Ophthalmology Market, Global, Revenue, ($bn), 2004–2011
Table 2: Ophthalmology Market, Global, Revenue, ($bn), 2011–2018
Table 3: Ophthalmology Market, Global, Annual Cost of Treatment, ($), 2004–2011
Table 4: Ophthalmology Market, Global, Annual Cost of Treatment, ($), 2011–2018
Table 5: Ophthalmology Market, Global, Treatment Usage Patterns (million), 2004–2011
Table 6: Ophthalmology Market, Global, Treatment Usage Patterns (million), 2011–2018
Table 7: Ophthalmology Market, the US, Revenue ($bn), 2004–2011
Table 8: Ophthalmology Market, the US, Revenue ($bn), 2011–2018
Table 9: Ophthalmology Market, the US, Annual Cost of Treatment ($), 2004–2011
Table 10: Ophthalmology Market, the US, Annual Cost of Treatment ($), 2011–2018
Table 11: Ophthalmology Market, the US, Treatment Usage Pattern (million), 2004–2011
Table 12: Ophthalmology Market, the US, Treatment Usage Pattern (million), 2011–2018
Table 13: Ophthalmology Market, Top Five Countries of Europe, Revenue ($m), 2004–2011
Table 14: Ophthalmology Market, Top Five Countries of Europe, Revenue ($m), 2011–2018
Table 15: Ophthalmology Market, Top Five Countries of Europe, Annual Cost of Treatment, ($), 2004–2011
Table 16: Ophthalmology Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2011–2018
Table 17: Ophthalmology Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004–2011
Table 18: Ophthalmology Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2011–2018
Table 19: Ophthalmology Market, Japan, Revenue ($m), 2004–2011
Table 20: Ophthalmology Market, Japan, Revenue ($m), 2011–2018
Table 21: Ophthalmology Market, Japan, Annual Cost of Treatment ($), 2004–2011
Table 22: Ophthalmology Market, Japan, Annual Cost of Treatment ($), 2011–2018
Table 23: Ophthalmology Market, Japan, Treatment Usage Pattern (million), 2004–2011
Table 24: Ophthalmology Market, Japan, Treatment Usage Pattern (million), 2011–2018
Table 25: Ophthalmology Market to 2018, Major Types of Glaucoma
Table 26: Ophthalmology Market to 2018, Mechanism of Action of Key Glaucoma Medications
Table 27: Ophthalmology Market to 2018, Global, Glaucoma, Revenue ($bn), 2004–2011
Table 28: Ophthalmology Market to 2018, Global, Glaucoma, Revenue Forecast ($bn), 2011–2018
Table 29: Ophthalmology Market to 2018, Global, Glaucoma, Annual Cost of Therapy ($), 2004–2011
Table 30: Ophthalmology Market to 2018, Global, Glaucoma, Annual Cost of Therapy ($), 2011–2018
Table 31: Ophthalmology Market to 2018, Global, Glaucoma, Treatment Usage Pattern (million), 2004–2011
Table 32: Ophthalmology Market to 2018, Global, Glaucoma, Treatment Usage Pattern (million), 2011–2018
Table 33: Ophthalmology Market to 2018, Global, Glaucoma, Geographical Segmentation of Revenues ($m), 2004–2011
Table 34: Ophthalmology Market to 2018, Global, Glaucoma, Geographical Segmentation of Revenues ($m), 2011–2018
Table 35: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Revenue ($m), 2004–2011
Table 36: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Revenue ($m), 2011–2018
Table 37: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Annual Cost of Therapy ($), 2004–2011
Table 38: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Annual Cost of Therapy ($), 2011–2018
Table 39: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Treatment Usage Pattern (million), 2004–2011
Table 40: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Treatment Usage Pattern (million), 2011–2018
Table 41: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Geographical Segmentation of Revenues ($m), 2004–2011
Table 42: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Geographical Segmentation of Revenues ($m), 2011–2018
Table 43: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, Revenue ($bn), 2004–2011
Table 44: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, Revenue ($bn), 2011–2018
Table 45: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, ACT ($), 2004–2011
Table 46: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, ACT ($), 2011–2018
Table 47: Ophthalmology Market to 2018, Global, Wet-Age Related Macular Degeneration, Treatment Usage Pattern (million), 2004–2011
Table 48: Ophthalmology Market to 2018, Global, Wet-Age Related Macular Degeneration, Treatment Usage Pattern (million), 2011–2018
Table 49: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Geographical Segmentation of Revenues ($m), 2004–2011
Table 50: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Geographical Segmentation of Revenues ($m), 2011–2018
Table 51: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Revenue ($m), 2011–2018
Table 52: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Annual Cost of Therapy ($), 2011–2018
Table 53: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Treatment Usage Pattern (‘000), 2011–2018
Table 54: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Geographical Segmentation of Revenues ($m), 2011–2018
Table 55: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Revenue ($bn), 2004–2011
Table 56: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Revenue ($bn), 2011–2018
Table 57: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Annual Cost of Therapy ($), 2004–2011
Table 58: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Annual Cost of Therapy ($), 2011–2018
Table 59: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Treatment Usage Pattern (million), 2004–2011
Table 60: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Treatment Usage Pattern (million), 2011–2018
Table 61: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Geographical Segmentation of Revenues ($m), 2004–2011
Table 62: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Geographical Segmentation of Revenues ($m), 2011–2018
Table 63: Ophthalmology Market to 2018, PBS Reimbursement List, Australia, 2012
Table 64: Ophthalmology Market to 2018, Global, Number of Deals by Geography, 2009– 2012
Table 65: Ophthalmology Market to 2018, Global, Number of Deals by Deal Value ($m), 2009– 2012
Table 66: Ophthalmology Market to 2018, Global, Number of Deals by Geography, 2009– 2012
Table 67: Ophthalmology Market to 2018, Global, Number of Deals by Geography, 2009– 2012
Table 68: Ophthalmology Market to 2018, Global, Number of Deals by Deal Value ($m), 2009– 2012
LIST OF FIGURES
Figure 1: Ophthalmology Market to 2018, Global, Revenue, ($bn), 2004–2018
Figure 2: Ophthalmology Market to 2018, Global, Annual Cost of Treatment, ($), 2004–2018
Figure 3: Ophthalmology Market, Global, Treatment Usage Patterns (million), 2004–2018
Figure 4: Ophthalmology Market to 2018, Global, Branded and Generic Market Share (%), 2011 and 2018
Figure 5: Ophthalmology Market, the US, Revenue ($bn), 2004–2018
Figure 6: Ophthalmology Market, the US, Annual Cost of Treatment ($), 2004–2018
Figure 7: Ophthalmology Market, the US, Treatment Usage Pattern (million), 2004–2018
Figure 8: Ophthalmology Market, Top Five Countries of Europe, Revenue ($m), 2004–2018
Figure 9: Ophthalmology Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2004–2018
Figure 10: Ophthalmology Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004–2018
Figure 11: Ophthalmology Market, Japan, Revenue ($m), 2004–2018
Figure 12: Ophthalmology Market, Japan, Annual Cost of Treatment ($), 2004–2018
Figure 13: Ophthalmology Market, Japan, Treatment Usage Pattern (million), 2004–2018
Figure 14: Ophthalmology Market to 2018, Global, Glaucoma, Revenue ($bn), 2004–2018
Figure 15: Ophthalmology Market to 2018, Global, Glaucoma, Annual Cost of Therapy ($), 2004–2018
Figure 16: Ophthalmology Market to 2018, Global, Glaucoma, Treatment Usage Pattern (million), 2004–2018
Figure 17: Ophthalmology Market to 2018, Glaucoma, Treatment Flow Algorithm
Figure 18: Ophthalmology Market to 2018, Glaucoma Market, Global, Branded and Generic Market Share (%), 2011 and 2018
Figure 19: Ophthalmology Market to 2018, Global, Glaucoma, Geographical Segmentation of Revenues ($m), 2004–2018
Figure 20: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Revenue ($m), 2004–2018
Figure 21: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Annual Cost of Therapy ($), 2004–2018
Figure 22: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Treatment Usage Pattern (million), 2004–2018
Figure 23: Ophthalmology Market to 2018, Allergic Conjunctivitis, Global, Treatment Flow Algorithm
Figure 24: Ophthalmology Market to 2018, Branded and Generic Market Share (%), 2011 and 2018
Figure 25: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Geographical Segmentation of Revenues ($m), 2004–2018
Figure 26: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, Revenue ($bn), 2004–2018
Figure 27: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, ACT ($), 2004–2018
Figure 28: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Treatment Usage Pattern (million), 2004–2018
Figure 29: Ophthalmology Market to 2018, Wet Age-Related Macular Degeneration, Global, Treatment Flow Algorithm
Figure 30: Ophthalmology Market to 2018, Wet-Age Related Macular Degeneration, Global, Branded and Generic Market Share (%), 2011–2018
Figure 31: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Geographical Segmentation of Revenues ($m), 2004–2018
Figure 32: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Revenue ($m), 2011–2018
Figure 33: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Annual Cost of Therapy ($), 2011–2018
Figure 34: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Treatment Usage Pattern (‘000), 2004–2018
Figure 35: Ophthalmology Market to 2018, Diabetic Macular Edema, Global, Treatment Flow Algorithm
Figure 36: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Geographical Segmentation of Revenues ($m), 2011–2018
Figure 37: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Revenue ($bn), 2004–2018
Figure 38: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Annual Cost of Therapy ($), 2004–2018
Figure 39: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Treatment Usage Pattern (million), 2004–2018
Figure 40: Ophthalmology Market to 2018, Dry Eye Syndrome, Global, Treatment Flow Algorithm, 2011
Figure 41: Ophthalmology Market to 2018, Dry Eye Syndrome, Global, Branded and Generic Market Share (%), 2011–2018
Figure 42: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Geographical Segmentation of Revenues ($m), 2004–2018
Figure 43: Ophthalmology Market to 2018, Allergan, SWOT, 2012
Figure 44: Ophthalmology Market to 2018, Merck Co & Inc, SWOT, 2012
Figure 45: Ophthalmology Market to 2018, Novartis AG, SWOT, 2012
Figure 46: Ophthalmology Market to 2018, Pfizer, SWOT, 2012
Figure 47: Ophthalmology Market to 2018, Roche, SWOT, 2012
Figure 48: Ophthalmology Market to 2018, Global, Number of Deals by Geography (%), 2009– 2012
Figure 49: Ophthalmology Market to 2018, Global, Segmentation of Deals by Value (%),2009– 2012
Figure 50: Ophthalmology Market to 2018 Global, Number of Deals by Geography (%),2009– 2012
Figure 51: Ophthalmology Market to 2018, Global, Number of Deals by Geography (%), 2009– 2012
Figure 52: Ophthalmology Market to 2018, Global, Number of Deals by Deal Value (%), 2009– 2012
Figure 53: GBI Research Market Forecasting Model
COMPANIES MENTIONED
Allergan, Inc.
Merck & Co Inc
Novartis AG
Pfizer
Roche
1.1 List Of Tables
1.2 List Of Figures
2 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - INTRODUCTION
2.1 Overview
3 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - MARKET OVERVIEW
3.1 IntrodUction
3.2 RevenUe
3.3 AnnUal Cost of Treatment
3.4 Treatment Usage Pattern
3.5 Branded and Generic Market Share
4 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - GEOGRAPHICAL LANDSCAPE
4.1 Geographical Break-Up
4.1.1 The US
4.1.2 Top Five CoUntries in EUrope
4.1.3 Japan
5 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - THERAPEUTIC LANDSCAPE
5.1 GlaUcoma Therapeutics Market
5.1.1 IntrodUction
5.1.2 RevenUe
5.1.3 AnnUal Cost of Treatment
5.1.4 Treatment Usage Pattern
5.1.5 Treatment Flow Algorithm
5.1.6 Branded and Generic Market Share
5.1.7 Drivers for the GlaUcoma Therapeutics Market
5.1.8 Restraints for GlaUcoma Therapeutics Market
5.1.9 Geographical Segmentation
5.2 Allergic ConjUnctivitis Therapeutics Market
5.2.1 IntrodUction
5.2.2 RevenUe
5.2.3 AnnUal Cost of Treatment
5.2.4 Treatment Usage Pattern
5.2.5 Treatment Flow Algorithm
5.2.6 Branded and Generic Market Share
5.2.7 Geographical Segmentation
5.3 Wet Age MacUlar Degeneration Therapeutics Market
5.3.1 IntrodUction
5.3.2 RevenUe
5.3.3 AnnUal Cost of Treatment
5.3.4 Treatment Usage Pattern
5.3.5 Treatment Flow Algorithm
5.3.6 Branded and Generic Market Share
5.3.7 Drivers for Wet Age-related MacUlar Degeneration Therapeutics Market
5.3.8 Restraints for Wet Age-Related MacUlar Degeneration Therapeutics Market
5.3.9 Geographical Segmentation
5.4 Diabetic MacUlar Edema Therapeutics Market
5.4.1 IntrodUction
5.4.2 RevenUe
5.4.3 AnnUal Cost of Treatment
5.4.4 Treatment Usage Pattern
5.4.5 Treatment Flow Algorithm
5.4.6 Drivers for Diabetic MacUlar Edema Therapeutics Market
5.4.7 Restraints for Diabetic MacUlar Edema Therapeutics Market
5.4.8 Geographical Segmentation
5.5 Dry Eye Syndrome, Therapeutics Market
5.5.1 IntrodUction
5.5.2 RevenUe
5.5.3 AnnUal Cost of Treatment
5.5.4 Treatment Usage Pattern
5.5.5 Treatment Flow Algorithm
5.5.6 Branded and Generic Market Share
5.5.7 Drivers for Dry Eye Syndrome Therapeutics Market
5.5.8 Restraints for Dry Eye Syndrome Therapeutics Market
5.5.9 Geographical Segmentation
6 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - APAC
6.1 India
6.1.1 Overview
6.1.2 Key Trends
6.1.3 Key Strategies
6.2 China
6.2.1 Overview
6.2.2 Key Trends
6.2.3 Key Strategies
6.3 AUstralia
6.3.1 Overview
6.3.2 Pricing and ReimbUrsement
7 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - PROFILES OF PROMISING PIPELINE PRODUCTS
7.1 IlUvien (flUocinolone acetonide)
7.1.1 Overview
7.1.2 Efficacy
7.1.3 Safety
7.1.4 Clinical StUdy Details
7.2 Rebamipide (OPC-12759E)
7.2.1 Overview
7.2.2 Clinical Details
7.3 RemUra (bromfenac)
7.3.1 Overview
7.3.2 Clinical details
7.4 OzUrdex (dexamethasone)
7.4.1 Overview
7.4.2 Clinical Details
7.5 ISTA -Ecabet SodiUm
7.5.1 Overview
7.6 Allergan’s Androgen Tear
7.6.1 Overview
8 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - COMPETITIVE LANDSCAPE
8.1 Allergan, Inc.
8.1.1 BUsiness Overview
8.1.2 SWOT
8.2 Merck & Co Inc
8.2.1 IntrodUction
8.2.2 SWOT
8.3 Novartis AG
8.3.1 IntrodUction
8.3.2 SWOT
8.4 Pfizer
8.4.1 BUsiness Description
8.4.2 SWOT
8.5 Roche
8.5.1 IntrodUction
8.5.2 SWOT
9 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - STRATEGIC CONSOLIDATIONS
9.1 Mergers and AcqUisitions
9.1.1 IntrodUction
9.1.2 Key Mergers and AcqUisitions Deals
9.1.3 Segmentation by Geography
9.1.4 Segmentation by Deal ValUe
9.2 Co-development Deals
9.2.1 Major Co-development Deals
9.2.2 Segmentation by Geography
9.3 Licensing Deals
9.3.1 Major Licensing Deals
9.3.2 Segmentation by Geography
9.3.3 Segmentation by ValUe
10 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Primary Research
10.5 Therapeutic Landscape
10.5.2 Market Size by Geography
10.6 Geographical Landscape
10.7 Pipeline Analysis
10.8 Competitive Landscape
10.8.1 Expert Panel Validation
10.9 Contact Us
10.10 Disclaimer
LIST OF TABLES
Table 1: Ophthalmology Market, Global, Revenue, ($bn), 2004–2011
Table 2: Ophthalmology Market, Global, Revenue, ($bn), 2011–2018
Table 3: Ophthalmology Market, Global, Annual Cost of Treatment, ($), 2004–2011
Table 4: Ophthalmology Market, Global, Annual Cost of Treatment, ($), 2011–2018
Table 5: Ophthalmology Market, Global, Treatment Usage Patterns (million), 2004–2011
Table 6: Ophthalmology Market, Global, Treatment Usage Patterns (million), 2011–2018
Table 7: Ophthalmology Market, the US, Revenue ($bn), 2004–2011
Table 8: Ophthalmology Market, the US, Revenue ($bn), 2011–2018
Table 9: Ophthalmology Market, the US, Annual Cost of Treatment ($), 2004–2011
Table 10: Ophthalmology Market, the US, Annual Cost of Treatment ($), 2011–2018
Table 11: Ophthalmology Market, the US, Treatment Usage Pattern (million), 2004–2011
Table 12: Ophthalmology Market, the US, Treatment Usage Pattern (million), 2011–2018
Table 13: Ophthalmology Market, Top Five Countries of Europe, Revenue ($m), 2004–2011
Table 14: Ophthalmology Market, Top Five Countries of Europe, Revenue ($m), 2011–2018
Table 15: Ophthalmology Market, Top Five Countries of Europe, Annual Cost of Treatment, ($), 2004–2011
Table 16: Ophthalmology Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2011–2018
Table 17: Ophthalmology Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004–2011
Table 18: Ophthalmology Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2011–2018
Table 19: Ophthalmology Market, Japan, Revenue ($m), 2004–2011
Table 20: Ophthalmology Market, Japan, Revenue ($m), 2011–2018
Table 21: Ophthalmology Market, Japan, Annual Cost of Treatment ($), 2004–2011
Table 22: Ophthalmology Market, Japan, Annual Cost of Treatment ($), 2011–2018
Table 23: Ophthalmology Market, Japan, Treatment Usage Pattern (million), 2004–2011
Table 24: Ophthalmology Market, Japan, Treatment Usage Pattern (million), 2011–2018
Table 25: Ophthalmology Market to 2018, Major Types of Glaucoma
Table 26: Ophthalmology Market to 2018, Mechanism of Action of Key Glaucoma Medications
Table 27: Ophthalmology Market to 2018, Global, Glaucoma, Revenue ($bn), 2004–2011
Table 28: Ophthalmology Market to 2018, Global, Glaucoma, Revenue Forecast ($bn), 2011–2018
Table 29: Ophthalmology Market to 2018, Global, Glaucoma, Annual Cost of Therapy ($), 2004–2011
Table 30: Ophthalmology Market to 2018, Global, Glaucoma, Annual Cost of Therapy ($), 2011–2018
Table 31: Ophthalmology Market to 2018, Global, Glaucoma, Treatment Usage Pattern (million), 2004–2011
Table 32: Ophthalmology Market to 2018, Global, Glaucoma, Treatment Usage Pattern (million), 2011–2018
Table 33: Ophthalmology Market to 2018, Global, Glaucoma, Geographical Segmentation of Revenues ($m), 2004–2011
Table 34: Ophthalmology Market to 2018, Global, Glaucoma, Geographical Segmentation of Revenues ($m), 2011–2018
Table 35: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Revenue ($m), 2004–2011
Table 36: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Revenue ($m), 2011–2018
Table 37: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Annual Cost of Therapy ($), 2004–2011
Table 38: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Annual Cost of Therapy ($), 2011–2018
Table 39: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Treatment Usage Pattern (million), 2004–2011
Table 40: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Treatment Usage Pattern (million), 2011–2018
Table 41: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Geographical Segmentation of Revenues ($m), 2004–2011
Table 42: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Geographical Segmentation of Revenues ($m), 2011–2018
Table 43: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, Revenue ($bn), 2004–2011
Table 44: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, Revenue ($bn), 2011–2018
Table 45: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, ACT ($), 2004–2011
Table 46: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, ACT ($), 2011–2018
Table 47: Ophthalmology Market to 2018, Global, Wet-Age Related Macular Degeneration, Treatment Usage Pattern (million), 2004–2011
Table 48: Ophthalmology Market to 2018, Global, Wet-Age Related Macular Degeneration, Treatment Usage Pattern (million), 2011–2018
Table 49: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Geographical Segmentation of Revenues ($m), 2004–2011
Table 50: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Geographical Segmentation of Revenues ($m), 2011–2018
Table 51: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Revenue ($m), 2011–2018
Table 52: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Annual Cost of Therapy ($), 2011–2018
Table 53: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Treatment Usage Pattern (‘000), 2011–2018
Table 54: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Geographical Segmentation of Revenues ($m), 2011–2018
Table 55: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Revenue ($bn), 2004–2011
Table 56: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Revenue ($bn), 2011–2018
Table 57: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Annual Cost of Therapy ($), 2004–2011
Table 58: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Annual Cost of Therapy ($), 2011–2018
Table 59: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Treatment Usage Pattern (million), 2004–2011
Table 60: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Treatment Usage Pattern (million), 2011–2018
Table 61: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Geographical Segmentation of Revenues ($m), 2004–2011
Table 62: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Geographical Segmentation of Revenues ($m), 2011–2018
Table 63: Ophthalmology Market to 2018, PBS Reimbursement List, Australia, 2012
Table 64: Ophthalmology Market to 2018, Global, Number of Deals by Geography, 2009– 2012
Table 65: Ophthalmology Market to 2018, Global, Number of Deals by Deal Value ($m), 2009– 2012
Table 66: Ophthalmology Market to 2018, Global, Number of Deals by Geography, 2009– 2012
Table 67: Ophthalmology Market to 2018, Global, Number of Deals by Geography, 2009– 2012
Table 68: Ophthalmology Market to 2018, Global, Number of Deals by Deal Value ($m), 2009– 2012
LIST OF FIGURES
Figure 1: Ophthalmology Market to 2018, Global, Revenue, ($bn), 2004–2018
Figure 2: Ophthalmology Market to 2018, Global, Annual Cost of Treatment, ($), 2004–2018
Figure 3: Ophthalmology Market, Global, Treatment Usage Patterns (million), 2004–2018
Figure 4: Ophthalmology Market to 2018, Global, Branded and Generic Market Share (%), 2011 and 2018
Figure 5: Ophthalmology Market, the US, Revenue ($bn), 2004–2018
Figure 6: Ophthalmology Market, the US, Annual Cost of Treatment ($), 2004–2018
Figure 7: Ophthalmology Market, the US, Treatment Usage Pattern (million), 2004–2018
Figure 8: Ophthalmology Market, Top Five Countries of Europe, Revenue ($m), 2004–2018
Figure 9: Ophthalmology Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2004–2018
Figure 10: Ophthalmology Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004–2018
Figure 11: Ophthalmology Market, Japan, Revenue ($m), 2004–2018
Figure 12: Ophthalmology Market, Japan, Annual Cost of Treatment ($), 2004–2018
Figure 13: Ophthalmology Market, Japan, Treatment Usage Pattern (million), 2004–2018
Figure 14: Ophthalmology Market to 2018, Global, Glaucoma, Revenue ($bn), 2004–2018
Figure 15: Ophthalmology Market to 2018, Global, Glaucoma, Annual Cost of Therapy ($), 2004–2018
Figure 16: Ophthalmology Market to 2018, Global, Glaucoma, Treatment Usage Pattern (million), 2004–2018
Figure 17: Ophthalmology Market to 2018, Glaucoma, Treatment Flow Algorithm
Figure 18: Ophthalmology Market to 2018, Glaucoma Market, Global, Branded and Generic Market Share (%), 2011 and 2018
Figure 19: Ophthalmology Market to 2018, Global, Glaucoma, Geographical Segmentation of Revenues ($m), 2004–2018
Figure 20: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Revenue ($m), 2004–2018
Figure 21: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Annual Cost of Therapy ($), 2004–2018
Figure 22: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Treatment Usage Pattern (million), 2004–2018
Figure 23: Ophthalmology Market to 2018, Allergic Conjunctivitis, Global, Treatment Flow Algorithm
Figure 24: Ophthalmology Market to 2018, Branded and Generic Market Share (%), 2011 and 2018
Figure 25: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Geographical Segmentation of Revenues ($m), 2004–2018
Figure 26: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, Revenue ($bn), 2004–2018
Figure 27: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, ACT ($), 2004–2018
Figure 28: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Treatment Usage Pattern (million), 2004–2018
Figure 29: Ophthalmology Market to 2018, Wet Age-Related Macular Degeneration, Global, Treatment Flow Algorithm
Figure 30: Ophthalmology Market to 2018, Wet-Age Related Macular Degeneration, Global, Branded and Generic Market Share (%), 2011–2018
Figure 31: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Geographical Segmentation of Revenues ($m), 2004–2018
Figure 32: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Revenue ($m), 2011–2018
Figure 33: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Annual Cost of Therapy ($), 2011–2018
Figure 34: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Treatment Usage Pattern (‘000), 2004–2018
Figure 35: Ophthalmology Market to 2018, Diabetic Macular Edema, Global, Treatment Flow Algorithm
Figure 36: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Geographical Segmentation of Revenues ($m), 2011–2018
Figure 37: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Revenue ($bn), 2004–2018
Figure 38: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Annual Cost of Therapy ($), 2004–2018
Figure 39: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Treatment Usage Pattern (million), 2004–2018
Figure 40: Ophthalmology Market to 2018, Dry Eye Syndrome, Global, Treatment Flow Algorithm, 2011
Figure 41: Ophthalmology Market to 2018, Dry Eye Syndrome, Global, Branded and Generic Market Share (%), 2011–2018
Figure 42: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Geographical Segmentation of Revenues ($m), 2004–2018
Figure 43: Ophthalmology Market to 2018, Allergan, SWOT, 2012
Figure 44: Ophthalmology Market to 2018, Merck Co & Inc, SWOT, 2012
Figure 45: Ophthalmology Market to 2018, Novartis AG, SWOT, 2012
Figure 46: Ophthalmology Market to 2018, Pfizer, SWOT, 2012
Figure 47: Ophthalmology Market to 2018, Roche, SWOT, 2012
Figure 48: Ophthalmology Market to 2018, Global, Number of Deals by Geography (%), 2009– 2012
Figure 49: Ophthalmology Market to 2018, Global, Segmentation of Deals by Value (%),2009– 2012
Figure 50: Ophthalmology Market to 2018 Global, Number of Deals by Geography (%),2009– 2012
Figure 51: Ophthalmology Market to 2018, Global, Number of Deals by Geography (%), 2009– 2012
Figure 52: Ophthalmology Market to 2018, Global, Number of Deals by Deal Value (%), 2009– 2012
Figure 53: GBI Research Market Forecasting Model
COMPANIES MENTIONED
Allergan, Inc.
Merck & Co Inc
Novartis AG
Pfizer
Roche
